IVA vs. SCPH, TELO, OGI, GLSI, ALIM, CAPR, MCRB, GOSS, ACRV, and PRQR
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include scPharmaceuticals (SCPH), Telomir Pharmaceuticals (TELO), Organigram (OGI), Greenwich LifeSciences (GLSI), Alimera Sciences (ALIM), Capricor Therapeutics (CAPR), Seres Therapeutics (MCRB), Gossamer Bio (GOSS), Acrivon Therapeutics (ACRV), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
19.1% of Inventiva shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 4.7% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Inventiva has a net margin of 0.00% compared to scPharmaceuticals' net margin of -403.22%. Inventiva's return on equity of 0.00% beat scPharmaceuticals' return on equity.
scPharmaceuticals received 140 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 66.10% of users gave scPharmaceuticals an outperform vote.
Inventiva has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.
Inventiva presently has a consensus price target of $17.00, indicating a potential upside of 373.54%. scPharmaceuticals has a consensus price target of $19.00, indicating a potential upside of 318.50%. Given Inventiva's higher possible upside, equities analysts clearly believe Inventiva is more favorable than scPharmaceuticals.
scPharmaceuticals has lower revenue, but higher earnings than Inventiva.
In the previous week, scPharmaceuticals had 1 more articles in the media than Inventiva. MarketBeat recorded 4 mentions for scPharmaceuticals and 3 mentions for Inventiva. Inventiva's average media sentiment score of 1.43 beat scPharmaceuticals' score of 0.47 indicating that Inventiva is being referred to more favorably in the media.
Summary
Inventiva beats scPharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
